Kyodo University Sets Up Drug Discovery Venture Company
This article was originally published in PharmAsia News
Executive Summary
On April 9, Kyodo University set up a venture company to search for active compounds that can be used for new drugs. With capital of ¥14 million, the new venture will utilize a research method developed by pharmacology Professor Yasushi Okuno, whose system quantifies information on chemical compounds that can be combined with protein, and uses a computer to process the different combinations in hope of finding active compounds in a more cost-efficient way. While the research has been used by overseas pharmaceutical companies, it is still an unknown area in Japan. The company hopes in the future to conduct contract research for pharmaceutical companies and enter the iPS cell drug research area. (Click here for more-Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.